BRAF and neoplasm: Yet, a recent Phase I trial (NCT01781429) did report a BRAF p.G469A-mutated head and neck cancer patient with partial response to ulixertinib (an ERK1/2 inhibitor) per RECIST criteria (> 30% tumor size reduction)74.